vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Broadway Financial Corp is the larger business by last-quarter revenue ($9.4M vs $9.1M, roughly 1.0× Protalix BioTherapeutics, Inc.). Broadway Financial Corp runs the higher net margin — 1934.0% vs -60.3%, a 1994.3% gap on every dollar of revenue. On growth, Broadway Financial Corp posted the faster year-over-year revenue change (10.1% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-13.0K). Over the past eight quarters, Broadway Financial Corp's revenue compounded faster (9.7% CAGR vs -6.7%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
BYFC vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $9.1M |
| Net Profit | $1.0M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | — | -51.1% |
| Net Margin | 1934.0% | -60.3% |
| Revenue YoY | 10.1% | -49.9% |
| Net Profit YoY | -21.8% | -184.8% |
| EPS (diluted) | $0.02 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $9.1M | ||
| Q3 25 | $9.0M | $17.9M | ||
| Q2 25 | $8.1M | $15.7M | ||
| Q1 25 | $8.3M | $10.1M | ||
| Q4 24 | $8.6M | $18.2M | ||
| Q3 24 | $8.7M | $18.0M | ||
| Q2 24 | $8.2M | $13.5M | ||
| Q1 24 | $7.8M | — |
| Q4 25 | $1.0M | $-5.5M | ||
| Q3 25 | $-23.9M | $2.4M | ||
| Q2 25 | $752.0K | $164.0K | ||
| Q1 25 | $-2.7M | $-3.6M | ||
| Q4 24 | $1.3M | $6.5M | ||
| Q3 24 | $516.0K | $3.2M | ||
| Q2 24 | $256.0K | $-2.2M | ||
| Q1 24 | $-154.0K | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | -51.1% | ||
| Q3 25 | -256.2% | 11.9% | ||
| Q2 25 | 12.8% | 7.5% | ||
| Q1 25 | -45.3% | -41.0% | ||
| Q4 24 | 21.7% | 39.6% | ||
| Q3 24 | 8.5% | 22.2% | ||
| Q2 24 | 4.8% | -18.0% | ||
| Q1 24 | -2.9% | — |
| Q4 25 | 1934.0% | -60.3% | ||
| Q3 25 | -264.2% | 13.2% | ||
| Q2 25 | 9.3% | 1.0% | ||
| Q1 25 | -32.3% | -35.8% | ||
| Q4 24 | 15.3% | 35.6% | ||
| Q3 24 | 5.9% | 18.0% | ||
| Q2 24 | 3.1% | -16.4% | ||
| Q1 24 | -2.0% | — |
| Q4 25 | $0.02 | $-0.06 | ||
| Q3 25 | $-2.86 | $0.03 | ||
| Q2 25 | $0.00 | $0.00 | ||
| Q1 25 | $-0.39 | $-0.05 | ||
| Q4 24 | $0.07 | $0.10 | ||
| Q3 24 | $-0.03 | $0.03 | ||
| Q2 24 | $0.02 | $-0.03 | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $48.2M |
| Total Assets | $1.3B | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $14.7M | ||
| Q3 25 | $19.7M | $13.6M | ||
| Q2 25 | $29.5M | $17.9M | ||
| Q1 25 | $15.8M | $19.5M | ||
| Q4 24 | $61.4M | $19.8M | ||
| Q3 24 | $97.1M | $27.4M | ||
| Q2 24 | $89.8M | $23.4M | ||
| Q1 24 | $67.1M | — |
| Q4 25 | $262.8M | $48.2M | ||
| Q3 25 | $261.7M | $52.9M | ||
| Q2 25 | $284.7M | $49.9M | ||
| Q1 25 | $283.6M | $45.2M | ||
| Q4 24 | $285.0M | $43.2M | ||
| Q3 24 | $286.2M | $32.4M | ||
| Q2 24 | $282.1M | $28.6M | ||
| Q1 24 | $281.1M | — |
| Q4 25 | $1.3B | $82.3M | ||
| Q3 25 | $1.3B | $82.3M | ||
| Q2 25 | $1.2B | $78.5M | ||
| Q1 25 | $1.3B | $73.9M | ||
| Q4 24 | $1.3B | $73.4M | ||
| Q3 24 | $1.4B | $61.6M | ||
| Q2 24 | $1.4B | $91.5M | ||
| Q1 24 | $1.4B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $2.0M |
| Free Cash FlowOCF − Capex | $-13.0K | $1.6M |
| FCF MarginFCF / Revenue | -0.1% | 17.8% |
| Capex IntensityCapex / Revenue | 2.6% | 4.4% |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $2.0M | ||
| Q3 25 | $3.8M | $-3.7M | ||
| Q2 25 | $3.0M | $-5.2M | ||
| Q1 25 | $-4.3M | $-5.1M | ||
| Q4 24 | $1.4M | $4.0M | ||
| Q3 24 | $6.1M | $4.1M | ||
| Q2 24 | $9.8M | $-3.6M | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | $-13.0K | $1.6M | ||
| Q3 25 | $3.7M | $-4.2M | ||
| Q2 25 | $3.0M | $-5.7M | ||
| Q1 25 | $-4.4M | $-5.4M | ||
| Q4 24 | $1.3M | $3.6M | ||
| Q3 24 | $6.1M | $4.0M | ||
| Q2 24 | $9.7M | $-3.8M | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | -0.1% | 17.8% | ||
| Q3 25 | 41.1% | -23.7% | ||
| Q2 25 | 37.0% | -36.2% | ||
| Q1 25 | -52.4% | -53.0% | ||
| Q4 24 | 14.7% | 19.6% | ||
| Q3 24 | 69.6% | 22.4% | ||
| Q2 24 | 118.9% | -28.1% | ||
| Q1 24 | -149.7% | — |
| Q4 25 | 2.6% | 4.4% | ||
| Q3 25 | 1.2% | 2.8% | ||
| Q2 25 | 0.2% | 2.8% | ||
| Q1 25 | 0.2% | 3.0% | ||
| Q4 24 | 1.6% | 2.3% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.5% | 1.3% | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | 4.00× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | 0.61× | ||
| Q3 24 | 11.85× | 1.27× | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BYFC
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
